Vital Technologies was founded in 2014 with the mission of creating a new and disruptive category of wellness products. Based on pharma-class R&D and dozens of human studies, Vital develops CUUR®: powerful fast-acting beverage recovery products, exclusively incorporating botanicals, amino acids, electrolytes and vitamins.
Our approach focuses on a multi-target integrative scientific approach to deliver powerful fast-acting products for the array of daily distress episodes (such as: energy, sports, learning, sleep, jetlag, alcohol, etc.) characterizing the modern and demanding lifestyle of healthy individuals across the globe.
CUUR® products are based on a patent-pending, microencapsulation technology platform, facilitating the delivery of ultra-dose, foul-tasting supplements in tasty, low-volume, functional beverages. The first line of CUUR® products facilitating rapid recovery from alcohol .
A seasoned entrepreneur, CEO, Chairman and VC in a series of life-science start-ups from a broad spectrum of life-science verticals, including EVOGENE (TASE: EVGN) and APPLOSONIX (TASE: APLS).
Doron previously served as the COO of Sabon (acquired by Rocher in 2017) and held senior operational positions at Hanita Polymers, NovoGI, C.T.S. and J&J (Omrix).
DR. MICHAEL FOX
Head of Formulation R&D
Prior to joining Vital Technologies, Dr. Fox spent 28 years at Teva as a technology and science lead in the development and commercialization of numerous solid and liquid formulations, both generic and ethical.
HEAD OF CONSUMER EXPERIENCE
Shmulik is an experienced food engineer, with over 25 years of experience in a variety of food and beverage companies. In his last position, Shmulik was was responsible for syrup R&D consumer experience in Soda Stream (NASDAQ: SODA), recently acquired by Pepsico.
VALENTIN FULGA, MD
An experienced pharma research executive.
Held senior management positions in product development & clinical research / development at Theravitae, Riolan Ophthalmics, Proneuron, Holo-Or, Pharmos and BTG.
PROF. MARK FILLMORE
A leading researcher in behavioral
pharmacology, substance abuse, and
DR. CHRIS ALFORD
A leading UK researcher with expertise in
Sleep; Psychopharmacology; Performance;
Sleep loss and fatigue; Driving; Natural
products and Functional foods; Social drugs;
psychophysiological measures including actimetry and EEG.
Former Chairman of the beer division of Constellation Brands (NYSE: STZ).
Served as the President and CEO of Tenth and Blake, MillerCoors $1B Craft and Imported Beer Division.